358 related articles for article (PubMed ID: 1648142)
1. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
[TBL] [Abstract][Full Text] [Related]
2. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
4. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Roth BJ; Johnson DH; Einhorn LH; Schacter LP; Cherng NC; Cohen HJ; Crawford J; Randolph JA; Goodlow JL; Broun GO
J Clin Oncol; 1992 Feb; 10(2):282-91. PubMed ID: 1310103
[TBL] [Abstract][Full Text] [Related]
7. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
9. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
[TBL] [Abstract][Full Text] [Related]
12. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy for small cell lung cancer].
Fukuoka M; Takada M; Masuda N; Furuse K; Saijo N; Ikegami H; Nishiwaki Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():225-31. PubMed ID: 7516450
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens.
Lowenbraun S; Birch R; Buchanan R; Krauss S; Durant J; Perez C; Mill W; Vollmer R; Ogden L
Cancer; 1984 Dec; 54(11):2344-50. PubMed ID: 6093979
[TBL] [Abstract][Full Text] [Related]
15. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
16. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
18. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
[TBL] [Abstract][Full Text] [Related]
19. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.
Ettinger DS; Finkelstein DM; Abeloff MD; Skeel RT; Stott PB; Frontiera MS; Bonomi PD
J Natl Cancer Inst; 1992 Jul; 84(14):1077-84. PubMed ID: 1320131
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
